Notes :

- The results for the quarter and nine months ended September 30, 2011 have been reviewed by the Audit
 Committee, approved by the Board of Directors and subjected to "Timited Review" by the Auditors of the
 Company, in compliance with Clause 41 of the Listing Agreement with Bombay Stock Exchange Limited.
- The Company changed its accounting year from year ended November 30 to year ended December 31 from the previous financial year onwards. Accordingly, the results for the current quarter and nine months are for the period ended September 30, 2011 and the corresponding previous quarter and nine months are for the period ended August 31, 2010.
- (a) Solivay Pharma India Limited (hereinafter referred to as "Solivay Pharma") has merged with Abbott India Limited (hereinafter referred to as "Company") on August 10, 2011 (Effective Date) according to the Scheme of Amaligamation (Scheme) sanctioned by the 10 per 10

(b) The amalgamation has been accounted for under the "pooling of interests" method as prescribed by Accounting Standard 14 (AS 14) "Accounting for Amalgamations". Accordingly, the assets, liabilities and reserves of Solvey Pharms as at December 1) onlive blent taken over at their book values after adjusting for (b) the distinct area of the control of the control

(c) Under the Scheme, the amalgamation has taken place with effect from January 1, 2011 (The Appointed Date). Accordingly the above results for the quarter and nine months ended September 30, 2011 include the results of Solvey Pharma. The results for the previous quarter and nine months ended August 31, 2010 and for 13 months ended December 31, 2010 are for Abbott India Limited before merger with Solvey Pharma.


(d) As on September 30, 2011, certain assets, liabilities and arrangements of Solvay Pharma are in the process of getting transferred to the Company.

- In view of the change of accounting year referred to in note 2 above and the amalgamation referred to in note 3 above, the results for the quarter and nine months ended September 30, 2011 are not comparable to those of the corresponding previous periods.
- 5. The Company continues to make strategic investments for expanding its field force and improve market coverage. The Company also continues to increase advertisement & promotional efforts to capture market share and increase brand coulty & customer awareness. These initiatives are impacting the near term profitability. Pursher, the other expenses for the nine months ended September 30, 2011 also includes integration & amalgametion expenses and stamp city.
- The Company (including Solvay Pharma) operates in one reportable business segment i.e. "Pharmaceuticals" and one reportable geographical segment i.e. "Within Indie".
- There was 1 investor complaint pending at the beginning of the quarter. The Company received 9 complaints from the investors, All complaints have been resolved and disposed off during the quarter. There was no complaint fying unresolved at the end of the quarter.
- 8. Figures for the prior period have been regrouped and/or reclassified wherever considered necessary.

Mumbai November 1, 2011

10









Tel : (91-22) 6797 8888 Fex : (91-22) 6797 8920 E-mail : webmaster@abbott.co.in Site : www.abbott.co.in

ŝr	Particulars	3 Months ended		9 Months ended		Previous Perlod from December 1,
No		September 30, 2011	August 31, 2010	September 30, 2011	August 31, 2010	2009 to December 31, 2010
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Net Sales/ Income from Operations	-				ľ
	(a) Gross Sales	402,16	249,90	1075,07	676,33	995,9
	Less : Excise Duty	527	1,60	13,10	4,20	6,1
	Net Sales	396,89	248,30	1061,97	672,13	989,8
	(b) Other Operating Income	13,61	6,39	29,21	17,26	29,0
2	Expenditure	23,34	(15,12)	12,80	(3,75)	(25,08
	(a) (Increase)/ Decrease in Stock in Trade & Work in Progress					
	(b) Consumption of Raw Materials	17,50	13,08	79,00	29,82	44,1
	(c) Purchase of Traded Goods	187,75	160,11	529,72	411,88	628,2
	(d) Employee Cost	47,89	25,43	129,75	71,48	111,2
	(e) Depreciation/ Amortisation	3,79	2,54	10,27	6,80	11,2
	(f) Other Expenditure	70,42	35,44	219,26	101,79	161,9
	(g) Total Expenditure	350,69	220,48	980,80	618,02	931,6 87,2
3	Profit from Operations before other Income and Interest (1-2)	59,81	34,21	110,38	71,37	
4	Other Income	488	1,75	13,88	397	6,9
5	Profit Before Interest (3+4)	64,69	35,96	124,26	75,34	94,1
6	Interest	-	-	2	1	
7	Profit Before Tax	64,69	35,96	124,24	75,33	94,1
8	Tax Expense (including current tax, deferred tax and prior period adjustments for the period)	21,06	12,06	40,73	25,56	33,2
9	Net Profit for the period	43,63	23,90	83,51	49,77	60,9
10	Paid-up Equity Share Capital (Face Value of the share - Rs 10/-)	21,25	13,68	21,25	13,68	13,6
11	Reserves excluding revaluation reserves (as per last audited Balance Sheet)					
12	Basic EPS and Diluted EPS for the periods (not annualised), year to date (not annualised) and for the previous period - Rs.	20.53	17.47	39.30	36.39	44.
13	Public shareholding		l		l	
	Number of Shares	5.315.254	42,47,056	5,315,254	42,47,056	42,47,0
	Percentage of Shareholding	25.01%	31.06%	25.01%	31.06%	31.06
14	Promoters and promoter group shareholding (a) Pledged/ Encumbered :					
	Number of Shares		-		-	
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	
	Percentage of Shares (as a % of the total share capital of the company) (b) Non - encumbered :	-	-	-	-	
	Number of Shares	15,934,048	94.28.184	15,934,048	94,28,184	94,28,1
	Percentage of Shares (as a % of the total	100%	100%	100%	100%	100
	shareholding of promoter and promoter group) Percentage of Shares (as 4 % of the total share capital of the company)	74.99%	68.94%	74.99%	68.94%	68.94

